Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MCN36 is a broad-spectrum micronutrient supplement consisting of 36 essential vitamins and minerals. It is primarily investigated as a non-pharmaceutical intervention for psychiatric conditions, most notably bipolar disorder. The formulation is designed to provide high doses of nutrients that serve as essential cofactors for enzymes involved in neurotransmitter synthesis, cellular metabolism, and mitochondrial function. Developed and studied extensively by researchers at the University of Calgary and the University of California, San Diego, MCN36 aims to stabilize mood and improve global functioning by addressing potential nutritional deficiencies or metabolic inefficiencies in the central nervous system. In commercial contexts, this specific 36-ingredient blend is typically identified as Daily Essential Nutrients (DEN).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MCN36.